
    
      The objective is to evaluate the safety and tolerability of the administration of two
      allergen extracts of dust mite mixtures at 200 DPP/ml (DP/MG/14-1 Dermatophagoides
      pteronyssinus / Blomia tropicalis and DP/MG/14-2 Dermatophagoides pteronyssinus /
      Lepidoglyphus destructor) using a rush build-up phase in patients with allergic rhinitis or
      rhinoconjunctivitis, with controlled asthma.
    
  